X hits on this document

6 views

0 shares

0 downloads

0 comments

1 / 2

FACT SHEET as of 31/12/2014

Industry

Holding

Pfizer

Pharmaceuticals

8.40%

Roche Holding

Pharmaceuticals

8.13%

GlaxoSmithKline

Pharmaceuticals

6.36%

Novartis

Pharmaceuticals

6.08%

Gilead Sciences

Biotechnology

5.13%

Johnson & Johnson

Pharmaceuticals

4.54%

International Health Care Portfolio1

Portfolio Objective and Strategy

The Portfolio seeks capital appreciation through investments on a worldwide basis in equity securities of companies that are engaged in health care and health science industries. A substantial portion of its portfolio will typically be invested in U.S. companies. Through a bottom-up selection process, the team attempts to determine market leaders with superior research, financial controls and marketing capabilities.

Portfolio Composition Industry Allocation

  • Pharmaceuticals 54.07%

  • Biotechnology 16.53%

  • Health Care Providers & Services

    • 12.83

      %

  • Health Care Equipment & Supplies

    • 12.82

      %

  • Life Sciences Tools & Services

    • 2.11

      %

  • Food & Staples Retailing 1.64%

  • *

    Source: AllianceBernstein.

    • Inception date: 12/02/2007, Class A (SGD);24/11/2000, Class

A (EUR);05/07/1995, Class A (USD).

  • The MSCI World Health Care Index is a free float-adjusted

market capitalization index that is designed to measure global developed market equity performance for the Health Care Sector. The MSCI World Health Care Index consists of 23 developed market country indices. An investor cannot invest directly in an index, and their results are not indicative of the performance for any specific investment, including an AB fund. Indices do not include sales charges or operating expenses associated with an investment in a mutual fund, which would reduce total returns.

  • ††

    As an annual percentage of average daily Net Asset Value.

For further details on the Management Fee, please refer to “Additional Information — Fees and Expenses” in section II of the fund’s Prospectus. For further information, or to obtain a copy of the Portfolio’s Prospectus, please contact your financial advisor.

United States 68.17% Switzerland 15.91% United Kingdom 8.58% Israel 2.08% Denmark 1.73% France 0.97% Italy 0.77% Germany 0.75% India 0.49% Other 0.55%

Holdings are expressed as a and may vary over time.

percentage of total investments

Profile*

  • Domicile: Luxembourg

  • Portfolio Inception Date:

05/07/1995 (Class A)

  • Fiscal Year End: 31 May

  • Net Assets: $383.57 million

  • Subscription/Redemption: Daily

  • Base Currency: U.S. Dollar

  • Convenience Pricing/Reporting Currencies: Singapore Dollar (S$), Euro

  • Benchmark: MSCI World Health Care Index‡

  • Order Placement Cut-off Time: 4:00 p.m. US ET

  • Management Fee: 1.80%††

  • Total # of Holdings: 61

Portfolio Management Team

John H. Fogarty, CFA Portfolio Manager

Vinay Tharpar Portfolio Manager & Senior Research

Analyst

Top Ten Holdings

Bryce Hill, CFA Portfolio Manager & Senior Research

Analyst

Country Allocation

Anthem

Services

4.45%

Health Care Equipment &

Medtronic

Supplies

3.45%

Allergan

Pharmaceuticals

3.20%

Bristol-Myers Squibb

Pharmaceuticals

2.99%

Total

Health Care Providers &

52.73%

Past performance is no guarantee of future results. Performance is shown in U.S. Dollar terms and, accordingly, the actual return achieved by a non-U.S. Dollar based investor may increase or decrease due to currency fluctuations.

Calendar Year Performance: Bid-to-Bid Class A†

Portfolio

Benchmark

36.3%

19.9%

18.1%

2009

26.4%

2010

2011

  • -

    0.3%

0.1%

2012

17.1%

18.9%

2.4%

9.5%

16.3%

17.5%

2013

2014 YTD

EQUITY

Document info
Document views6
Page views6
Page last viewedTue Oct 25 22:47:26 UTC 2016
Pages2
Paragraphs232
Words1235

Comments